Immunome reported positive top-line Phase III results for varegacestat in progressing desmoid tumors, showing a statistically significant and clinically meaningful improvement in progression‑free survival. The oral gamma‑secretase inhibitor reduced the risk of disease progression or death by 84%, prompting the company to plan a U.S. NDA submission in the second quarter of next year. Data were presented by Immunome and summarized in BioCentury coverage and company releases.